210 related articles for article (PubMed ID: 9396395)
1. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer.
Moore MJ; Tannock IF; Ernst DS; Huan S; Murray N
J Clin Oncol; 1997 Dec; 15(12):3441-5. PubMed ID: 9396395
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group.
Moore MJ; Winquist EW; Murray N; Tannock IF; Huan S; Bennett K; Walsh W; Seymour L
J Clin Oncol; 1999 Sep; 17(9):2876-81. PubMed ID: 10561365
[TBL] [Abstract][Full Text] [Related]
3. Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: effective treatment of patients with poor prognostic features.
Shannon C; Crombie C; Brooks A; Lau H; Drummond M; Gurney H
Ann Oncol; 2001 Jul; 12(7):947-52. PubMed ID: 11521800
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer.
Stadler WM; Kuzel T; Roth B; Raghavan D; Dorr FA
J Clin Oncol; 1997 Nov; 15(11):3394-8. PubMed ID: 9363871
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the urothelium: a pilot study.
Culine S; Rebillard X; Iborra F; Mottet N; Faix A; Ayuso D; Pinguet F
Anticancer Res; 2003; 23(2C):1903-6. PubMed ID: 12820476
[TBL] [Abstract][Full Text] [Related]
6. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.
Bellmunt J; Guillem V; Paz-Ares L; González-Larriba JL; Carles J; Batiste-Alentorn E; Sáenz A; López-Brea M; Font A; Nogué M; Bastús R; Climent MA; de la Cruz JJ; Albanell J; Banús JM; Gallardo E; Diaz-Rubio E; Cortés-Funes H; Baselga J
J Clin Oncol; 2000 Sep; 18(18):3247-55. PubMed ID: 10986057
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma.
Pagliaro LC; Millikan RE; Tu SM; Williams D; Daliani D; Papandreou CN; Logothetis CJ
J Clin Oncol; 2002 Jul; 20(13):2965-70. PubMed ID: 12089226
[TBL] [Abstract][Full Text] [Related]
8. Combined chemoradiotherapy with gemcitabine in patients with locally advanced inoperable transitional cell carcinoma of the urinary bladder and/or in patients ineligible for surgery: a phase I trial.
De Santis M; Bachner M; Cerveny M; Kametriser G; Steininger T; Königsberg R; Schratter-Sehn A; Sedlmayer F; Dittrich C
Ann Oncol; 2014 Sep; 25(9):1789-1794. PubMed ID: 24936582
[TBL] [Abstract][Full Text] [Related]
9. The first Slovak experience with second-line vinflunine in advanced urothelial carcinomas.
Palacka P; Mego M; Obertova J; Chovanec M; Sycova-Mila Z; Mardiak J
Klin Onkol; 2014; 27(6):429-33. PubMed ID: 25493582
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer.
Lorusso V; Pollera CF; Antimi M; Luporini G; Gridelli C; Frassineti GL; Oliva C; Pacini M; De Lena M
Eur J Cancer; 1998 Jul; 34(8):1208-12. PubMed ID: 9849481
[TBL] [Abstract][Full Text] [Related]
11. Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients.
Kitamura H; Takahashi A; Hotta H; Kato R; Kunishima Y; Takei F; Horita H; Masumori N;
Int J Urol; 2015 Oct; 22(10):911-4. PubMed ID: 26087891
[TBL] [Abstract][Full Text] [Related]
12. Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract.
Dodd PM; McCaffrey JA; Hilton S; Mazumdar M; Herr H; Kelly WK; Icasiano E; Boyle MG; Bajorin DF
J Clin Oncol; 2000 Feb; 18(4):840-6. PubMed ID: 10673526
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine plus cisplatin for advanced transitional cell carcinoma of the urinary tract: a phase II multicenter trial.
Lorusso V; Manzione L; De Vita F; Antimi M; Selvaggi FP; De Lena M
J Urol; 2000 Jul; 164(1):53-6. PubMed ID: 10840423
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine plus docetaxel as first-line biweekly therapy in locally advanced and/or metastatic urothelial carcinoma: a phase II study.
Neri B; Vannini L; Giordano C; Grifoni R; Pantaleo P; Baldazzi V; Crisci A; Lapini A; Raugei A; Carini M
Anticancer Drugs; 2007 Nov; 18(10):1207-11. PubMed ID: 17893522
[TBL] [Abstract][Full Text] [Related]
15. Intravenous 3-weekly paclitaxel and metronomic oral cyclophosphamide in patients with advanced urothelial cancer previously treated with gemcitabine and platinum.
Park JH; Lee JL
Cancer Chemother Pharmacol; 2015 Feb; 75(2):247-54. PubMed ID: 25428517
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma.
Alva A; Daignault S; Smith DC; Hussain M
Invest New Drugs; 2014 Feb; 32(1):188-94. PubMed ID: 24318901
[TBL] [Abstract][Full Text] [Related]
17. Platinum-free combination chemotherapy in patients with advanced or metastatic transitional cell carcinoma.
Lara PN; Meyers FJ; Law LY; Dawson NA; Houston J; Lauder I; Edelman MJ
Cancer; 2004 Jan; 100(1):82-8. PubMed ID: 14692027
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine in transitional cell carcinoma of the urothelium.
von der Maase H
Expert Rev Anticancer Ther; 2003 Feb; 3(1):11-9. PubMed ID: 12597345
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy with gemcitabine, paclitaxel, and cisplatin in the treatment of patients with advanced transitional cell carcinoma of the urothelium.
Ecke TH; Bartel P; Koch S; Ruttloff J; Theissig F
Oncol Rep; 2006 Dec; 16(6):1381-8. PubMed ID: 17089065
[TBL] [Abstract][Full Text] [Related]
20. Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial.
von der Maase H; Andersen L; Crinò L; Weinknecht S; Dogliotti L
Ann Oncol; 1999 Dec; 10(12):1461-5. PubMed ID: 10643537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]